re: AUPH - Aurinia Pharmaceuticals

quote:

---

Oh well, up 200% this week in the crypto world.

---

I wish I understood this crypto crap, even after reading the threads on MT and others, I am still lost.

quote:

---

For AUPH? What's today and tomorrow? Earnings?

---

No, earnings won’t be relevant until they bring a drug to market.

I’m just thinking about the chart. On Wednesday we popped to $5.75 briefly and I’d love to go into next week with 5.50 support continuing that upward grind.

Catalysts to come before Q3

F it. I’m in for 40 shares.

quote:

---

No, earnings won’t be relevant until they bring a drug to market.

I’m just thinking about the chart. On Wednesday we popped to $5.75 briefly and I’d love to go into next week with 5.50 support continuing that upward grind.

---

So they have no product on the market? What supports their value?

Dummies like us

quote:

---

So they have no product on the market? What supports their value?

---

probably the same thing that supports $25 Twitter and $350 Tesla. Expectations...

Aurinia might be the first ever Pharmaceutical to cure Lupus Nephritis, and if phase II is any indicator, they will.
It’s all in this thread if you care to read.

Consensus price target of $12, climbing institutional ownership including a few major players, and Michael Goodman (pharma guy) on Twitter is pretty high on them too.

Also, their CEO created the current standard of care for Lupus. AUPH is just tweaking/improving the drug. It’s a solid gamble.

I have hopes that YoungManOldMan’s $225 investment turns into $1,200 over the next two years.

Now you think I wanted to type all that shite on my phone?? No! ...but I could go on

Damn. Nice. You must be pretty confident as well.
I’m between 1k - 2k

I have bought and sold to take some profit when it got close to $10, then added to my position on the recent lows....I currently hold about 2500 shares.

quote:

---

As we reflect back on the past year, one thing is clear – there has been significant progress, not only in awareness, but also in lupus research and advocacy efforts to secure additional research funding for lupus. We are encouraged by the advances of 2017 and look forward to reporting on more successes during 2018 and beyond, with great hope of a better quality of life for all people affected by lupus!

---

quote:

---

Great Progress in the Development of an Arsenal of New Treatments - Results of several clinical trials provided good reasons for people with lupus to remain hopeful that more effective and tolerable treatments are right around the corner.

Voclosporin - A phase IIb clinical study of voclosporin for treating lupus nephritis (lupus affecting the kidneys) showed nearly half of the participants who received a low dose of voclosporin, along with standard of care, achieved complete remission after 48 weeks of treatment. The research is continuing and a phase III trial, Aurora, began in late May of 2017.

---

lupus.org